Home – Neurimmune

Transforming the wisdom of life

into promising drug candidates

Neurimmune’s scientists discovered with the Reverse Translational Medicine technology the anti-ATTR antibody Cliramitug (formerly ALXN2220, NI006) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury. These programs are currently evaluated in clinical trials.

Neurimmune pipeline

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and researchers translate genetic information of lymphocyte transcripts from elderly human donors into therapeutic antibodies. Evolutionarily optimized and wisely elected antibodies with preferred activities combine high affinity with target selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform

Scientific publications

View all

N Engl J Med - 2023

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Sci Transl Med. - 2018

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Nature - 2016

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

News

View all

25.09.2025 | Press Release

AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer.

04.09.2025 | Press Release

AL-S Pharma today announced positive topline results from the Phase 2 clinical study evaluating AP-101, a potential first-in-class, disease-modifying treatment for amyotrophic lateral sclerosis (ALS).

26.08.2025 | Company News

Neurimmune today announced that new data from the open-label extension of the Phase I trial of cliramitug (formerly NI006, ALXN2220) for the treatment of ATTR-CM will be presented at the ESC Congress 2025 in Madrid.

Driven by the passion for life

to help patients around the world

Roger M Nitsch, MD

CEO

View details

Christoph Hock, MD

CMO

View details

Jan Grimm, PhD

CSO

View details